Friday, October 02, 2015 8:20:54 PM
Those against the FDA reclassification and emergence of ActiPatch type devices and the eventuality of major reductions in the epidemic consumption of harmful, addictive chemical pain management drugs either still use an abacus, write snail mail letters, use lanterns, rotary dial phones, buses to go from NY to LA, keep travel locally by horse and go to bed when it gets dark, or, have ulterior motives. Not my issue, I am only interested in 2015 and the future of pain management using BIEL type devices instead of harmful drugs. In my opinion, anyone bashing BIEL is endorsing the continuing epidemic use of harmful drugs. There will always be a place for chemical drugs, but never again to the extent that Americans are consuming today. This is being proven now in England where tot OTC sales of ActiPatch are escalating through the roof.
Good luck with all the yesteryear. BIEL is here, it is an American company that miniaturized a scientific innovation that works and the UK was intelligent enough to endorse ActiPatch, Canada too, and it's already helping tens, hundreds of thousands in England to better and more safely manage their pain. Our approval process takes longer, part of the cost of doing business here, but the BIEL/ActiPatch/ALLAY train is coming to Walgreens, CVS, Rite Aid, Walmart and all the rest, soon!
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM